Holobiome final presentation 7

[Dx.3] Holobiome

Initial Hypothesis: We provide personalized disease management tool for IBD patientsthat monitors the gut microbiome to predict oncoming flares.

1.4 Million IBD patients

Mild/Moderate patients

Internet access

Vision: Envisioning a healthy gut microbiome for everyone

Number of Interviews: 93

Initial Market Size:

Holobiome

Kei FujimuraPost-doc at UCSF, Microbial ecologistPicker/Hustler

Shoko IwaiPost-doc at UCSF, Microbial ecologist, BioinformaticsHacker/Hustler

Yosuke KamimuraPost-doc at UCSF, Immunologist, VirologistDesigner/Hustler

David HanzelDiagnostics expertMentor

Week 1

• Provide personalized prognositic for IBD patients in order to subvert flares and foresee colorectal cancer symptoms.

• Reduce risk of misdiagnsosis and time through a non-invasive and safe diagnostic tool.

• Access to sample processing equipment (e.g. thermocycler, sequencer, biosafety cabinet) and lab technician or outsource all lab work

• Computers / servers• Pipelines• Data analysts

• Posts by patient advocates on Crohns & Colitis Foundation forums, patientslikeme.com, etc.

• Web account and app

• Seminars led by local thought leaders

• MD to MD connections

• Inflammatory Bowel Disease (IBD) Patients

• General practice MDs, DOs, Gastroenterologists, Naturopaths

.• Generate personalized

baseline reports and track changes over time.

• Online lifestyle diary to track effects of meds and diet on biome over time

• Dedicated personal assistance

• Online community• Personal physicians

• Dedicated e-commerce• Direct sales.

• Subscription fee (multiple samples)

• Batch ordering for physicians

• Fixed menu pricing.

Joint venture with Metabolon, who will provide metabolomic data.

Buyer / suppliers: Illumina, MoBio

Physician organizations:Inflammatory Bowel Disase Center @ UCSF

CPMC Research Institute

Patient organizations and patient advocates:Crohns & Colitis Foundation

Fixed costs:• Lab space and/or

office space• Salaries• Server• Website maintenance• Lab equipment

Sample processing:• Sample

processing kits• Stool collection

kits

Risk reduction for patients and physicians

• value-driven• Variable costs

based on service levels

IBD patientsPhysicians

Week 1

























kits



IBD patientsPhysicians

VPRisk reduction for patients and physicians• Provide personalized prognositic for

IBD patients in order to subvert flares and foresee colorectal cancer symptoms.


CS• Inflammatory

Bowel Disease (IBD) Patients

• General practice MDs, DOs, Gastroenterologists, Naturopaths

Our HypothesisPatients and doctors want the patients’ gut microbiome monitored in order to predict their next flares.What we found out…

Interesting, but we need evidence. (19/19)

http://www.cdc.gov/ibd/http://www.assetprotectionlawjournal.com/articles/physician-asset-protection/

Week 1-4: Our products were not ready for doctors and unnecessary for IBD patients

I’m not interested. I want solutions, not another monitoring device! (5/7)-patient with mild or moderate IBD

We were depressed…….

Explore other customer segments!

Breakfast meeting

Week 5: So then…we decided to include









Inflammatory Bowel Disease (IBD) Patients

General practice MDs, DOs, Gastroenterologists, Naturopaths



















kits




IBD patientsPhysiciansHealth conscious people

Health conscious people

Validation that their lifestyle reflects healthy gut microbiome

http://www.9lot.com/2013/04/important-nutritional-products-needed-today.html

Week 5: Health conscious people were not interested

Our HypothesisHealth conscious people may want to know gut microbiome as a marker for healthiness.

I’m not interested. I feel great and have no GI issues. (8/8)

What we found out…










General practice MDs, DOs, Gastroenterologists, Naturopaths



















kits




Quantified Self

Quantify microbiome as a token of healthiness

Week 6: Switched to Quantified Selfies who love data about

Week 6: QS’s value propositions were too diverse

Our HypothesisQuantified self want to monitor their gut microbiome

Sleep cycle (2/9)

Mood (1/9)

Blood glucose levels (1/9)

Exercise (2/9)

Diet (2/9)

Blood pressure (2/9)

http://www.innovation-alliance.net/

Weight (2/9)

Heart rate (1/9)

I want to track…

Ketones (1/9)

We got depressed again……Back to square one…

Patients want to remain in remission ‘naturally’ without side effects

Week 7: Provide specialized probiotics

• Through our interviews, we noticed most of the patients are taking probiotics (12/14).

• Current probiotics do not work the same for everyone.

• Specialized probiotics based on ‘microbiome types’.

Remain in remission

Cost savings

HR: Bioinformatics & Data analysts

Computers/servers

Pipelines

Patent

Trade secret (probiotics composition)

Finance: Research grants

Dedicated E-commerce

Direct Sales

GI doctors prescribe probiotics

Direct Sales


Insurance company

Research and publish

Online lifestyle diary to track effects of meds and diet on biome over time

GET: Ads on patient foundation

GET: Clinical and scientific presentation

GET: KOLs of GI specialist

GET: Dossier to medical director

KEEP: Dedicated personal assistance

KEEP: Customer surveys

GROW: Referrals

Fixed menu pricing: $200/month

Get our codes covered

Suppliers: Metabolon will provide metabolomic data.

Suppliers: SeqWright will provide DNA isolation and sequencing.

Suppliers: KLAIRE LABS will grow bacteria and formulate into pills

FDA


office space• Salaries• Server and website

maintenance

• Shipping and handling• Value-driven• Variable costs based on

service levels

Final canvas: Specialized probiotics for IBD patients

What we found out overall….

• IBD patients want solutions not another way to monitor.

• For our goals reflected in our mission statement, the science of using the microbiome is still ~ 5-10 years away.

Our Investment Readiness Level

1 & 2. Basic Technology Research

3. Product/Market Fit

2. Problem/Solution

1. Hypotheses (Canvas)

• Now!

• Research CompanyTechnology Readiness Level

Holobiome final presentation 7

Education

Transcript of Holobiome final presentation 7